Evaluating the Impact of Elacestrant Use in Clinical Practice for Patients With ER+/HER2-Metastasized Breast Cancer
Identifying the impact of elacestrant in clinical practice for patients with ER+/HER2- metastatic breast cancer.
EMERALD Subgroup Analysis in Patients With Visceral and Bone Metastases: Clinical Implication
A comprehensive review of the safety, efficacy, and subgroup analysis of the EMERALD Trial.
Treatment Landscape in ER+/HER2- Metastatic Breast Cancer and Unmet Needs
A discussion of the disease state, current therapies, and treatment challenges in ER+/HER2- metastatic breast cancer.
plasmaMATCH Findings Play an Important Role in the Breast Cancer Setting
Joyce A. O'Shaughnessy, MD, discusses the phase II plasmaMATCH trial, which investigated plasma-based molecular profiling of patients with advanced breast cancer to inform therapeutic choices.